Table 1.

 Summary of the Formulation Conditions

Base Buffera	pHb	Excipientc	Storage Conditions	Methods
Initial Screening of pH and Additives
Na-citrate	3.0	100 mM NaCl, 0.25 M sucrose, 0.01% Tween 80	Initial/no storage; 40°C, 4 days; 2 mg/mLd	DLS, DSF
Glycine	3.5
Na-acetate	4.0
Na-acetate	4.5
Na-acetate	5.0
Succinate	5.5
Histidine	6.0
Histidine	6.5
Imidazole	7.0
Glycyl–glycine	8.0
Glycine	9.0
Glycine	10.0
Stability Studies Under Accelerated Storage Conditions
Na-citrate	3.3	100 mM NaCl, 0.25 M sucrose, 0.05% Tween 80	Initial/no storage; 40°C, 8 weeks; 12 mg/mLd	SAXSe, UV280 nm, SE-HPLC, LabChip
Na-acetate	5.0
Histidine	6.5
Na-phosphate	7.4
Tris–HCl	8.5
Stability Studies Under Normal Storage Conditions
Histidinef	6.5	0.25 M sucrose	Initial/no storage; 5°C, 8 weeks; 25°C, 8 weeks; 2 mg/mLd	SE-HPLC, iCE
Na-phosphateg	7.4	100 mM NaCl

^aFinal concentration of the base buffers was 50 mM.

^bMeasured at room temperature.

^cExcipients were included respectively to each of the base buffers.

^dAntibody concentration during storage.

^eOnly the samples at initial time point were measured by SAXS.

^fFormulation A.

^gFormulation B.